Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
25-Mar-2026 | 338 | 352.65 | 337.65 | 345.3 | 39,477 | 36,20,96,892.1 | 4,15,347 |
27-Mar-2026 | 345 | 355 | 341.8 | 349.6 | 32,592 | 26,06,54,973.5 | 3,26,022 |
30-Mar-2026 | 345.1 | 352.9 | 338.05 | 348.9 | 26,343 | 22,77,57,550.7 | 3,28,818 |
01-Apr-2026 | 360 | 379.1 | 350.6 | 374.7 | 31,404 | 28,63,93,588.7 | 2,95,496 |
02-Apr-2026 | 370 | 393 | 364.15 | 388.9 | 27,089 | 31,71,61,180.05 | 4,17,671 |
06-Apr-2026 | 388.9 | 394.45 | 368.45 | 391.5 | 28,429 | 24,83,51,570.45 | 2,64,131 |
07-Apr-2026 | 392.9 | 396.9 | 385.9 | 391.35 | 15,046 | 10,94,66,594.4 | 1,28,320 |
08-Apr-2026 | 409.75 | 410 | 393.2 | 403.7 | 15,703 | 18,01,18,965.9 | 2,20,930 |
09-Apr-2026 | 401.4 | 426.9 | 395 | 419 | 29,169 | 31,94,38,564.6 | 3,20,385 |
10-Apr-2026 | 424 | 425 | 412.05 | 420.1 | 13,833 | 15,03,23,615.65 | 1,49,656 |
13-Apr-2026 | 410.05 | 423 | 404.55 | 415.9 | 11,470 | 9,87,21,636.9 | 1,07,643 |
15-Apr-2026 | 420 | 424.45 | 409 | 414.2 | 17,670 | 21,63,48,833.5 | 2,04,673 |
16-Apr-2026 | 415.95 | 420.05 | 406.95 | 412 | 10,546 | 10,21,17,442.5 | 1,02,339 |
17-Apr-2026 | 410 | 416.65 | 407 | 410.55 | 11,916 | 11,64,40,017.95 | 1,34,952 |
20-Apr-2026 | 415 | 429.9 | 402.9 | 411.25 | 23,613 | 24,91,36,852.2 | 2,38,493 |
21-Apr-2026 | 412.6 | 414 | 400.4 | 405.25 | 15,787 | 12,73,97,170.75 | 1,50,237 |
22-Apr-2026 | 400.9 | 413.8 | 396.5 | 408.35 | 16,615 | 15,83,12,687.45 | 1,61,960 |
23-Apr-2026 | 407.9 | 436.4 | 405.05 | 427.6 | 43,121 | 59,98,89,337.3 | 6,71,553 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
